ScholarIQanswers from OpenAlex
Health Outcomes Solutions (United States)
InstitutionResearch output, impact & collaborations
Health Outcomes Solutions (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Health Outcomes Solutions (United States)?
ScholarIQrecord summary
Health Outcomes Solutions (United States) is a research organisation in Winter Park, US. OpenAlex records 2,926 works and 150,378 citations for it. 689 researchers list it as their most recent affiliation.
How many works does Health Outcomes Solutions (United States) have?
ScholarIQindexed works
Health Outcomes Solutions (United States) has 2,926 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Health Outcomes Solutions (United States) have?
ScholarIQcitation count
Health Outcomes Solutions (United States) has 150,378 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Health Outcomes Solutions (United States)?
ScholarIQresearcher count
Health Outcomes Solutions (United States) has 689 researchers in the ScholarIQ index.
What is the average h-index at Health Outcomes Solutions (United States)?
ScholarIQavg h-index
Health Outcomes Solutions (United States) has an average h-index of 37.7 in OpenAlex.
What is the ROR of Health Outcomes Solutions (United States)?
ScholarIQror
The ROR for Health Outcomes Solutions (United States) is on the source record.
What is the OpenAlex record for Health Outcomes Solutions (United States)?
ScholarIQopenalex
The OpenAlex for Health Outcomes Solutions (United States) is on the source record.
Who are the most-cited researchers behind Health Outcomes Solutions (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Health Outcomes Solutions (United States)?
ScholarIQmost cited works
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, Alain H. Rook, Pierluigi Porcu, Sarah McCue Horwitz, Sean Whittaker, Y. Tokura, Maarten H. Vermeer, Pier Luigi Zinzani, Lubomir Sokol, Stephen Morris, Ellen J. Kim, Pablo L. Ortiz‐Romero, Herbert Eradat, Julia Scarisbrick, Athanasios Tsianakas, Craig A. Elmets, Stéphane Dalle, David C. Fisher, Ahmad Halwani, Brian Poligone, John P. Greer, Maria Teresa Fierro, Amit Khot, Alison J. Moskowitz, Amy Musiek, Andrei R. Shustov, Barbara Pro, Larisa J. Geskin, Karen M. Dwyer, Junji Moriya, Mollie Leoni, Jeffrey S. Humphrey, Stacie Hudgens, Dmitri O. Grebennik, Kensei Tobinai, Madeleine Duvic, Sunil Abhyankar, Oleg E. Akilov, Önder Alpdoğan, M. Beylot‐Barry, Erin Boh, Dolores Caballero, Richard Cowan, Brigitte Dréno, Reinhard Dummer, Timothy S. Fenske, Francine Foss, Noriko Fukuhara, Pratyush Giri, Koji Habe, Toshihisa Hamada, Kiyohiko Hatake, Shinsuke Iida, Osamu Ishikawa, Lars Iversen, Eiji Kiyohara, Hiroshi Koga, Neil J. Korman, Bryone J. Kuss, Zanetta S. Lamar, Frederick Lansigan, Mary Jo Lechowicz, Adam Lerner, Nina Magnolo, Lawrence A. Mark, Tomomitsu Miyagaki, Javier Muñoz, Jan P. Nicolay, Kaoru Nishiwaki, Hiroyuki Okamoto, Mikio Ohtsuka, Theresa Pacheco, Christiane Querfeld, Ronald Peter Rapini, Shigetoshi Sano, Maiko Tanaka, Michael D. Tharp, Jiro Uehara, Hidefumi Wada, Jillian Wells, Ryan A. Wilcox, Basem M. William, Kentaro Yonekura
Measuring the side effects of taxane therapy in oncology
David Cella, Amy H. Peterman, Stacie Hudgens, Kimberly Webster, Mark A. Socinski
Bone Marrow Transplants from HLA-Identical Siblings as Compared with Chemotherapy for Children with Acute Lymphoblastic Leukemia in a Second Remission
A. John Barrett, Mary M. Horowitz, Brad H. Pollock, Mei-Jie Zhang, Mortimer M. Bortin, George R. Buchanan, Bruce M. Camitta, Judith Ochs, John Graham‐Pole, Philip A. Rowlings, Alfred A. Rimm, John P. Klein, Jonathan J. Shuster, Kathleen A. Sobocinski, Robert Peter Gale
Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study
Elizabeth A. Hahn, G. Alastair Glendenning, Mark Sorensen, Stacie Hudgens, Brian Druker, François Guilhot, Richard A. Larson, Stephen G. O’Brien, Deborah Dobrez, Martee L. Hensley, David Cella
Ambulatory Continuous Femoral Nerve Blocks Decrease Time to Discharge Readiness after Tricompartment Total Knee Arthroplasty
Brian M. Ilfeld, Linda T. Le, R. Scott Meyer, Edward R. Mariano, Krista Vandenborne, Pamela W. Duncan, Daniel I. Sessler, F. Kayser Enneking, Jonathan J. Shuster, Douglas W. Theriaque, Linda F. Berry, Eugene H. Spadoni, Peter F. Gearen
How much of the research on Health Outcomes Solutions (United States) is open access?
ScholarIQopen access share
58%OPEN ACCESS